药物及未来候选药物。
Drugs and future candidates.
作者信息
Andersson Karl-Erik
机构信息
Institute for Regenerative Medicine, Physiology & Pharmacology, Urology, Molecular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.
出版信息
Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S131-3. doi: 10.5489/cuaj.11182.
Abstract
Antimuscarinic drugs are still first-line treatment for the symptoms of overactive bladder (OAB) and are associated with good initial response rates. Adverse effects and decreasing efficacy over the longer term do, however, limit their overall effectiveness. As such, alternatives to antimuscarinics are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters involved in the symptoms of the OAB has sparked interest in pharmacologic manipulation of both peripheral and central pathophysiology. Some of the treatments currently under investigation are discussed in this review.
摘要
抗毒蕈碱药物仍然是治疗膀胱过度活动症（OAB）症状的一线药物，且初始有效率良好。然而，其不良反应以及长期疗效降低确实限制了它们的整体有效性。因此，需要抗毒蕈碱药物的替代物。对尿路上皮功能作用的认识、膀胱充盈期间自发的肌细胞活动以及参与OAB症状的神经递质多样性，引发了人们对外周和中枢病理生理学药物调控的兴趣。本综述讨论了目前正在研究的一些治疗方法。
相似文献
1
Drugs and future candidates.药物及未来候选药物。
Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S131-3. doi: 10.5489/cuaj.11182.
2
Prospective pharmacologic therapies for the overactive bladder.治疗膀胱过度活动症的潜在药物治疗方法。
Ther Adv Urol. 2009 Jun;1(2):71-83. doi: 10.1177/1756287209103937.
3
Pharmacotherapy of the overactive bladder.膀胱过度活动症的药物治疗。
Discov Med. 2009 Oct;8(42):118-24.
4
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.膀胱过度活动症治疗的新进展：聚焦米拉贝隆和肉毒杆菌毒素 A。
Ther Clin Risk Manag. 2013;9:161-70. doi: 10.2147/TCRM.S33052. Epub 2013 Apr 18.
5
Emerging drugs for treatment of overactive bladder and detrusor overactivity.治疗膀胱过度活动症和逼尿肌过度活动症的新型药物
Expert Opin Emerg Drugs. 2008 Sep;13(3):431-46. doi: 10.1517/14728214.13.3.431.
6
Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.治疗抗毒蕈碱药物治疗之外的膀胱过度活动症症状：当前和未来的治疗方法。
Postgrad Med. 2012 May;124(3):16-27. doi: 10.3810/pgm.2012.05.2544.
7
Antimuscarinic mechanisms and the overactive detrusor: an update.抗毒蕈碱机制与逼尿肌过度活动：更新。
Eur Urol. 2011 Mar;59(3):377-86. doi: 10.1016/j.eururo.2010.11.040. Epub 2010 Dec 8.
8
The medical treatment of overactive bladder, including current and future treatments.膀胱过度活动症的治疗，包括当前和未来的治疗方法。
Expert Opin Pharmacother. 2011 May;12(7):1041-55. doi: 10.1517/14656566.2011.554399. Epub 2011 Feb 8.
9
Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.难治性逼尿肌过度活动——潜在药理学及机制
Int J Clin Pract Suppl. 2006 Dec(151):8-16. doi: 10.1111/j.1742-1241.2006.01184.x.
10
Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.抗毒蕈碱药物治疗膀胱过度活动症的基础和临床方面。
Pharmacol Ther. 2018 Sep;189:130-148. doi: 10.1016/j.pharmthera.2018.04.010. Epub 2018 Apr 27.
引用本文的文献
1
Pirt reduces bladder overactivity by inhibiting purinergic receptor P2X3.吡咯烷酮可通过抑制嘌呤能受体 P2X3 来减少膀胱过度活动。
Nat Commun. 2015 Jul 7;6:7650. doi: 10.1038/ncomms8650.
2
Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction.膀胱过度活动症综合征以及前列腺素和磷酸二酯酶的潜在作用：引言
Nephrourol Mon. 2013 Sep;5(4):934-45. doi: 10.5812/numonthly.14087. Epub 2013 Sep 10.
3
The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder.吲哚美辛对分离正常豚鼠膀胱中蕈毒碱诱导收缩的影响。
BMC Urol. 2013 Feb 7;13:8. doi: 10.1186/1471-2490-13-8.
本文引用的文献
1
ATP and P2X purinoceptors in urinary tract disorders.三磷酸腺苷（ATP）与P2X嘌呤受体在泌尿系统疾病中的作用
Handb Exp Pharmacol. 2011(202):485-526. doi: 10.1007/978-3-642-16499-6_22.
2
Can urinary nerve growth factor be a biomarker for overactive bladder?尿神经生长因子能否作为膀胱过度活动症的生物标志物？
Rev Urol. 2010 Spring;12(2-3):e69-77.
3
Prostaglandin receptor EP1 and EP2 site in guinea pig bladder urothelium and lamina propria.豚鼠膀胱尿路上皮和固有层中的前列腺素受体 EP1 和 EP2 位点。
J Urol. 2010 Mar;183(3):1241-7. doi: 10.1016/j.juro.2009.11.004. Epub 2010 Jan 22.
4
Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat.CL316,243（一种β3-肾上腺素能受体激动剂）和膀胱内前列腺素 E2 对大鼠初级膀胱传入活动的影响。
Neurourol Urodyn. 2010 Jun;29(5):771-6. doi: 10.1002/nau.20826.
5
GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models.GRC - 6211是一种新型口服特异性瞬时受体电位香草酸亚型1（TRPV1）拮抗剂，可降低膀胱炎动物模型中的膀胱过度活动和有害膀胱传入。
J Urol. 2009 Jan;181(1):379-86. doi: 10.1016/j.juro.2008.08.121. Epub 2008 Nov 17.
6
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.一项随机、安慰剂对照研究，旨在评估每日两次服用伐地那非治疗良性前列腺增生继发下尿路症状的疗效。
Eur Urol. 2008 Jun;53(6):1236-44. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb 4.
7
Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder.硫化氢敏感的TRPA1离子通道在大鼠膀胱中的分布与功能
Eur Urol. 2008 Feb;53(2):391-9. doi: 10.1016/j.eururo.2007.10.024. Epub 2007 Oct 22.
8
Duloxetine compared with placebo for treating women with symptoms of overactive bladder.度洛西汀与安慰剂治疗膀胱过度活动症女性症状的比较。
BJU Int. 2007 Aug;100(2):337-45. doi: 10.1111/j.1464-410X.2007.06980.x. Epub 2007 May 19.
9
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.他达拉非可缓解良性前列腺增生继发的下尿路症状。
J Urol. 2007 Apr;177(4):1401-7. doi: 10.1016/j.juro.2006.11.037.
10
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.M3受体选择性毒蕈碱拮抗剂达非那新对大鼠盆神经膀胱传入活动的影响。
Eur Urol. 2007 Sep;52(3):842-7. doi: 10.1016/j.eururo.2007.02.057. Epub 2007 Mar 6.
Zotero 插件